ACTR Annual Report 2025

Greetings from Dr. Kaiping Zhang and the Editorial Office of AME Clinical Trials Review (ACTR).

We are glad to present the 2025 Annual Report of ACTR, which has shown the author statistics, pageviews and visits of ACTR articles, as well as previews of upcoming reviews in the Education Channel and commentaries planned for the coming year.

Read More>>

AME and Wolters Kluwer aim to expand access to global medical research through new collaboration

The agreement broadens the reach of nearly 50 Open Access titles, contributing globally to over 5,000 articles

October 2, 2025 — Wolters Kluwer Health announced a new collaboration with AME Publishing Company, an Open Access publisher specializing in medical journals and books, headquartered in Hong Kong, China.

Read More>>

Reviewer of the Month (2025)

In 2025, ACTR reviewers continue to make outstanding contributions to the peer review process. They demonstrated professional effort and enthusiasm in their reviews and provided comments that genuinely help the authors to enhance their work.

Hereby, we would like to highlight some of our outstanding reviewers, with a brief interview of their thoughts and insights as a reviewer. Allow us to express our heartfelt gratitude for their tremendous effort and valuable contributions to the scientific process.

Read More>>

Interviews with Outstanding Authors (2025)

In 2025, many authors shared their insights on clinical trials in our journal. Their articles published with us have received very well feedback in the field and stimulate a lot of discussions and new insights among the peers.

Hereby, we would like to highlight some of our outstanding authors who have been making immense efforts in their research fields, with a brief interview of their unique perspectives and insightful views as authors.

Read More>>

The role of lisocabtagene maraleucel for relapsed/refractory follicular lymphoma: a commentary

Abigail T. Huetteman, Julio C. Chavez
Editorial Commentary｜February 25, 2026
doi: 10.21037/actr-25-18

Read More>>

Encorafenib, cetuximab and chemotherapy: a mole against BRAF mutant metastatic colorectal cancer

Benoist Chibaudel
Editorial Commentary｜February 25, 2026
doi: 10.21037/actr-25-80

Read More>>

From the PACIFIC to the ADRIATIC: a literature review of 38 years of failed maintenance trials in small cell lung cancer post-chemoradiation

Alexandria Lee, Misako Nagasaka, Sai-Hong Ignatius Ou, Zhaohui Liao Arter
Review Article｜February 25, 2026
doi: 10.21037/actr-25-71

Read More>>

First-line treatment strategies and potential prognostic factors in patients with KRAS G12C-mutant non-small cell lung cancer

Malak Alharbi, Nour Nassour, Vaishali Deenadayalan, Grace K. Dy
Review Article｜February 25, 2026
doi: 10.21037/actr-25-63

Read More>>

The role of minimal residual disease measurement in multiple myeloma

Bhavesh Mohan Lal, Nikhil Vojjala, Nikhila Sampath Kumar, Carolina Schinke
Review Article｜February 25, 2026
doi: 10.21037/actr-25-66

Read More>>

Clinical advancements in total neoadjuvant therapy for locally advanced rectal cancer: a narrative review

Angelo Pirozzi, Celine Hoyek, Naohiro Okano, Leticia Assad Maia Sandoval, Binbin Zheng-Lin, Oluseyi Abidoye, Cody Eslinger, Mohamad Bassam Sonbol, Mitesh J. Borad, Tanios S. Bekaii-Saab
Review Article｜February 25, 2026
doi: 10.21037/actr-25-58

Read More>>